MMP2 and triple-A syndrome: Kurobe et al. also demonstrated that MMP-2 expression in PVAT was significantly decreased by systemic treatment with eplerenone, a selective mineralocorticoid receptor antagonist, which concomitantly inhibited AAA formation (Kurobe et al., 2013).